PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.43%
Revenue growth under 50% of 3088.T's 3.69%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-0.51%
Negative gross profit growth while 3088.T is at 1.24%. Joel Greenblatt would examine cost competitiveness or demand decline.
51.44%
EBIT growth above 1.5x 3088.T's 14.28%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
1.06%
Operating income growth under 50% of 3088.T's 5.45%. Michael Burry would be concerned about deeper cost or sales issues.
52.44%
Net income growth above 1.5x 3088.T's 17.65%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
52.44%
EPS growth above 1.5x 3088.T's 18.13%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
52.44%
Diluted EPS growth above 1.5x 3088.T's 18.13%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.00%
Share change of 0.00% while 3088.T is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.00%
Diluted share change of 0.00% while 3088.T is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.55%
10Y revenue/share CAGR above 1.5x 3088.T's 34.71%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
59.61%
5Y revenue/share CAGR above 1.5x 3088.T's 6.76%. David Dodd would look for consistent product or market expansions fueling outperformance.
26.86%
3Y revenue/share CAGR above 1.5x 3088.T's 2.58%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
100.00%
Positive long-term OCF/share growth while 3088.T is negative. John Neff would see a structural advantage in sustained cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
222.32%
Similar net income/share CAGR to 3088.T's 242.59%. Walter Schloss would see parallel tailwinds or expansions for both firms.
177.62%
5Y net income/share CAGR above 1.5x 3088.T's 0.04%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
107.89%
3Y net income/share CAGR above 1.5x 3088.T's 2.55%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
194.93%
10Y equity/share CAGR 1.25-1.5x 3088.T's 130.84%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
125.91%
5Y equity/share CAGR above 1.5x 3088.T's 43.06%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
59.94%
3Y equity/share CAGR above 1.5x 3088.T's 21.48%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while 3088.T invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
10.26%
AR growth well above 3088.T's 18.14%. Michael Burry fears inflated revenue or higher default risk in the near future.
-1.27%
Inventory is declining while 3088.T stands at 3.29%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.24%
Asset growth above 1.5x 3088.T's 0.80%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.71%
BV/share growth above 1.5x 3088.T's 1.08%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-5.89%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-0.94%
We cut SG&A while 3088.T invests at 0.11%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.